Werewolf Therapeutics, Inc. (HOWL): Nasdaq/NYSE listing notice — Werewolf Therapeutics receives Nasdaq deficiency notice for low bid price; has until Nov 10, 2025 to cure

Werewolf Therapeutics, Inc.

Stock bid price closed below $1.00 for 30 consecutive business days, triggering Nasdaq deficiency notice.
Company has 180 calendar days until November 10, 2025 to regain compliance by closing at $1.00 for 10 consecutive business days.
If not cured, company may seek transfer to Nasdaq Capital Market for additional 180-day period, subject to other listing standards.
Failure to cure could lead to delisting; company plans to monitor bid price and evaluate available options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Werewolf Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

May 13, 2025, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common

View on SEC.gov

Browse all listing & compliance notices →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-120910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.